Abstract: Objective To analyze the clinical effect of terlipressin combined with ascites concentration and reinfusion on refractory ascites patients with cirrhosis. Methods 54 cirrhotic patients with obstinate ascites were divided into observation group (n = 27) and control group (n = 27) from May 2017 to October 2019. The control group was treated with ascites concentration and reinfusion, and the observation group was treated with terlipressin on the basis of the control group. Results At the end of 14 day observation, the abdominal circumferences of patients in observation and control groups were (86.3±4.3) cm and (89.8±6.4) cm, the depth of ascites were (31.5±8.4) mm and (53.3±9.4) mm, serum bilirubin levels were (60.8±9.8) μmol/L and (71.5±8.7) μmol / L, serum albumin levels were (33.3±3.0) g / L and (30.0±3.1) g / L, serum BUN were (6.8±1.8) μmol / L and (9.8±2.8) μmol / L, sCr were (104.5±14.4) μmol / L and (133.8±15.3) μmol / L, significantly different between the two groups (P<0.05), and the 24 h urine volume were (1088.3±285.9)mL and (1385.9±337.9) mL, the hospital stays were (28.8±3.7) d and (38.5±8.3) d, and the ascites concentration and reinfusion were (4.3±1.4) times and (10.7±3.2) times, respectively, significantly different between the two groups (P<0.05). Conclusion The application of terlipressin combined with ascites concentration and reinfusion could reduce the amount of ascites, improve the functions of liver and kidney, shorten the length of hospital stay, and needs further investigation.

Key words: Liver cirrhosis, Refractory ascites, Terlipressin, Ascites concentration and reinfusion, Therapy